Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lifecore Biomedical (LCBM) -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Happy who wrote (25)	10/23/1999 8:05:00 AM
From: Mike	Respond to of 43

Earnings were released and wondering if anyone was able to get detailed info? The earnings met expectations and wondering if in the numbers things are positive or negative. First the HA business was up over 120% vs same qtr ly. It was noted that the increase was due to opthalmic and venterinary sales. What was the contribution of Intergel sales in Europe? Are sales still very slow to increase? Was this growth mainly due to a big order from Alcon? Next the Oral division had a sales increase of only 2%. Can anyone explain this low growth quarter for this division? In the past we have seen consistent 15-25% growth from the Oral side. Now I know this past qtr is the slowest for LCBM but just looking for clarification. Thanks in advance. MHat

To: Mr. Happy who wrote (25)	11/17/1999 4:11:00 AM
From: Mike	Respond to of 43

Is anyone attending the annual shareholders meeting? Can anyone give us a recap as to what happened? Any update on how the Oral Restorative divisions sales are going this current qtr? The sales for this division last qtr were not good. Lets hope the new products are selling well. Any comments as we go forward? When do we expect to make an announcement on the date of panel for Intergel? Lets hope it is soon. Today was the day they were initially scheduled to meet. Thanks in advance, Mike

To: Mr. Happy who wrote (25)	12/9/1999 10:36:00 PM
From: Mike	Respond to of 43

Yes. Now lets hope the panel doesnt cancel again. Only kidding. Great move on the stock today. Who agrees that there was a leak of this news? Pretty obvious huh. INTERGEL Adhesion Prevention Solution PMA Review Scheduled for January 12 Advisory Panel Meeting CHASKA, Minn.--(BW HealthWire)--Dec. 9, 1999--LIFECORE BIOMEDICAL, INC. (Nasdaq:LCBM) announced today that the Food and Drug Administration has reported in the Federal Register that it has scheduled a review of the Company's premarket approval (PMA) application for its ferric hyaluronate product, INTERGEL(TM) Adhesion Prevention Solution, at a January 12, 2000 meeting of the General and Plastic Surgery Devices Advisory Panel. INTERGEL(TM) Solution has been under evaluation in pivotal human clinical trials since March 1996. The studies are designed to evaluate the reduction of post-surgical adhesion formation after gynecological laparotomy and laparoscopy procedures. The PMA application currently under review represents the laparotomy portion of those clinical evaluations and was filed with the FDA in March 1999. The FDA formally accepted the PMA for expedited review in May 1999. The laparoscopy clinical trial is expected to be filed as a PMA supplement at a later date. Lifecore believes that the laparotomy clinical trial data currently under PMA review demonstrates that INTERGEL(TM) Solution is safe and effective in significantly reducing the incidence, extent, and severity of post-surgical adhesions. The Gynecare Division of Ethicon, Inc., a Johnson & Johnson Company, currently markets Lifecore's ferric hyaluronate outside the US in selected countries under the trademark, INTERGEL(TM) Adhesion Prevention Solution. Certain statements in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements implying timing or outcome of the FDA review process are subject to change. Because of numerous risks and uncertainties in the complex regulatory aspects of Lifecore's business activity, actual results may differ materially from those implied. Investors are strongly cautioned to review more detailed discussions of those risks presented in the Company's reports on Forms 10-Q and 10-K. Lifecore Biomedical manufactures biomaterials and surgical devices for use in various surgical markets and provides specialized contract aseptic manufacturing services. Additional general corporate information is available on the Internet at lifecore.com CONTACT: Lifecore Biomedical, Chaska 612-368-4300 James W. Bracke, President and CEO Dennis J. Allingham, EVP and CFO Colleen M. Olson, VP of Corporate Administrative Operations KEYWORD: MINNESOTA BW1633 DEC 09,1999 15:30 PACIFIC 18:30 EASTERN

To: Mr. Happy who wrote (25)	12/27/1999 9:52:00 PM
From: Mike	Read Replies (1) \| Respond to of 43

Is there anyone out there that may know what this means to LCBM? Is this a favor that Alcon is giving to LCBM to help out until Intergel is released? This is interesting and wondering if it means anything? Did LCBM give Alcon get a discount for paying this money up front? Lifecore Receives $5,000,000 Customer Advance CHASKA, Minn.--(BW HealthWire)--Dec. 27, 1999--LIFECORE BIOMEDICAL, INC. (Nasdaq:LCBM) announced today that it has received a $5,000,000 advance from its largest customer, Alcon Laboratories, Inc., ("Alcon"). The cash advance is to be repaid through future ophthalmic sodium hyaluronate shipments to Alcon. Lifecore supplies hyaluronate to Alcon pursuant to a longstanding supply agreement that began with Alcon's predecessor, CILCO, Inc, in 1983. The Company's ophthalmic sodium hyaluronate is used in Viscoat(R) Ophthalmic Viscoelastic Solution, a liquid device deployed in the eye during cataract surgeries. The contract was renewed in December of 1998 with a sixth consecutive extension of terms and currently runs through December of 2000. No additional financial details were released about the transaction. Dr. Jim Bracke, President and CEO of Lifecore, stated: "When a large marketing partner such as Alcon will work with a smaller company in this fashion to help manage cash flow, it speaks volumes about the quality of Lifecore's relationship and the importance of its product." Certain statements in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements implying timing or outcome of this or future financings are subject to change. Because of numerous risks and uncertainties in the complex regulatory aspects of Lifecore's business activity, actual results may differ materially from those implied. Investors are strongly cautioned to review more detailed discussions of those risks presented in the Company's reports on Forms 10-Q and 10-K. Lifecore Biomedical manufactures biomaterials and surgical devices for use in various surgical markets and provides specialized contract aseptic manufacturing services. Additional general corporate information is available on the Internet at lifecore.com